Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib

Boehringer Ingelheim180 enrolled

Overview

Multi-center, non-interventional, prospective cohort study aiming to enroll 240 Idiopathic Pulmonary Fibrosis patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across Greece.

Study Type

OBSERVATIONAL

Enrollment

180

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

NintedanibDRUG

diagnosed IPF patients initiating treatment with nintedanib

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients ≥40 years of age. * Patients that have signed Informed Consent Form. * Treatment naive patients with an initial IPF diagnosis no more than 3 months prior to enrolment according to 2011 American Thoracic Society (ATS)/ European Respiratory Society (ERS)/ Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT) guidelines who are initiating treatment with nintedanib (as monotherapy for IPF) the latest on the enrollement day or have initiated treatment with nintedanib (as monotherapy for IPF) within the past 7 days prior to enrolment. * Patients for whom the decision to prescribe therapy with nintedanib according to the locally approved product's Summary of Product Characteristics (SmPC) has already been taken prior to their enrolment in the study and is clearly separated from the physician's decision to include the patient in the current study. * Patients that are able to read, understand and complete the study specific questionnaires. Exclusion Criteria: * Treatment with nintedanib for more than 7 days prior to study enrolment. * Patients receiving a combination therapy of nintedanib \& pirfenidone for IPF. * Patients that meet any of the contraindications to the administration of the study drug nintedanib according to the approved SmPC. * Prior treatment with pirfenidone or other treatment for IPF. * Participation in an interventional study. * Patients currently receive treatment with any investigational drug/device/intervention or have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) before the initiation of therapy with nintedanib.

Locations (10)

University General Hospital of Evros

Alexandroupoli, Greece

Gen. Hosp. of Chest Diseases "Sotiria", Univ. Resp. Med.

Athens, Greece

University General Hospital Attikon

Athens, Greece

Outcomes

Primary Outcomes

Mean Change From Baseline in Health Related Quality of Life (HRQoL) Using SGRQ Score at 3 Months

St. George's Respiratory Questionnaire (SGRQ) is a 50-item questionnaire assessing 3 domains: symptoms (frequency and severity of respiratory symptoms), activity (activities that cause, or are limited by, breathlessness) and psychosocial impact (range of aspects concerning social functioning and the psychological impact of the disease) that was self-completed by patients at all study visits. The total SGRQ score and the score for each domain range from 0 to 100, with higher scores indicating worse HRQoL. Change from baseline defined as: post baseline - baseline value. Mixed model analysis with fixed effects of visit, GAPBSL stage, FVCBSL (cut off \<70%), DLCOBSL (cut off \<40%), number of comorbidities and baseline score by visit interaction.

Time frame: At baseline and at 3 months.

Mean Change From Baseline in Health Related Quality of Life (HRQoL) Using SGRQ Score at 6 Months

Time frame: At baseline and at 6 months.

Mean Change From Baseline in Health Related Quality of Life (HRQoL) Using SGRQ Score at 9 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Mean Change From Baseline of Dyspnoea Burden With Modified Medical Research Council Scale (mMRC) Score

The modified Medical Research Council (mMRC) consists of a 5-level rating scale (grades 0-4) based on the patient's perception of dyspnoea (perception of breathlessness) in daily activities, with grade 4 representing the most severe category. Change from baseline defined as: post baseline - baseline value. Mixed model analysis with fixed effects of visit, GAPBSL stage, FVCBSL (cut off \<70%), DLCOBSL (cut off \<40%), number of comorbidities and baseline score by visit interaction.

Time frame: At baseline and at 3, 6, 9, and 12 months.

Mean Change Form Baseline to the Follow up Period of Cough Burden With Cough-Visual Analogue Scale (Cough-VAS)

Patients were asked at each study visit to rate their perceived intensity of cough due to their IPF on a vertical VAS ranging from 0 to 100, with endpoints labelled as 'no cough' ('100'), 'moderate cough' ('50'), and 'intense cough' ('0'). Change from baseline defined as: post baseline - baseline value. Mixed model analysis with fixed effects of visit, GAPBSL stage, FVCBSL (cut off \<70%), DLCOBSL (cut off \<40%), number of comorbidities and baseline score by visit interaction.

Time frame: At baseline, and at 3, 6, 9, and 12 months.

Percentage of Adhered Patients to Nintedanib Treatment With Simplified Medication Adherence Questionnaire (SMAQ)

SMAQ consisted of 6 items of which, four were dichotomous (Yes/No), one was Likert-type and one was an open question. A patient was considered as non-adherent, if he/she gave a positive response to any of the qualitative questions, and in terms of quantification, if the patient had lost one of the two daily doses for more than 2 days or had not taken medication for more than four complete days during the past 3 months.

Time frame: At 3, 6, 9, and 12 months.

Mean Change of Anxiety in IPF Patients Treated With Nintedanib From Baseline to Follow up Period Via Generalized Anxiety Disorder Screener (GAD-7) Questionnaire

Generalized Anxiety Disorder Screener (GAD-7) is a 7-item instrument validated for anxiety evaluation that could be used in an outpatient setting. Patients were asked at all study visits to indicate how often they experienced anxiety symptoms over the previous two weeks on a 4-point Likert scale as follows: 0 = 'not at all'; 1 = 'several days'; 2 = 'more than half the days'; and 3 = 'nearly every day'. Change from baseline defined as: post baseline - baseline value. Mixed model analysis with fixed effects of visit, GAPBSL stage, FVCBSL (cut off \<70%), DLCOBSL (cut off \<40%), number of comorbidities and baseline score by visit interaction.

Time frame: At baseline, and at 3, 6, 9, and 12 months.

Percentage of Patients That Use Long Term Oxygen Treatment (LTOT)

Percentage of patients that use Long Term Oxygen Treatment (LTOT) is presented.

Time frame: At baseline, and at 3, 6, 9, and 12 months.